<DOC>
	<DOCNO>NCT00088855</DOCNO>
	<brief_summary>This phase II trial study side effect well bortezomib pegylated liposomal doxorubicin hydrochloride work treat patient multiple myeloma experiencing symptom receive prior treatment . Bortezomib pegylated liposomal doxorubicin hydrochloride may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Bortezomib Pegylated Liposomal Doxorubicin Hydrochloride Treating Patients With Previously Untreated Symptomatic Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To evaluate complete response ( CR ) + near-complete response ( nCR ) rate bortezomib/pegylated liposomal doxorubicin ( pegylated liposomal doxorubicin hydrochloride ) regimen patient previously untreated , symptomatic multiple myeloma . II . To evaluate toxicity bortezomib/pegylated liposomal doxorubicin regimen patient previously untreated , symptomatic multiple myeloma . SECONDARY OBJECTIVES : I . To evaluate overall response rate , include patient CR , nCR , partial response ( PR ) , bortezomib/pegylated liposomal doxorubicin regimen patient previously untreated , symptomatic multiple myeloma . II . To evaluate impact therapy bortezomib/pegylated liposomal doxorubicin regimen ability collect peripheral blood stem cell patient go subsequent autologous stem cell transplantation . III . To evaluate time progression ( TTP ) patient receive bortezomib/pegylated liposomal doxorubicin therapy , go autologous stem cell transplantation go transplantation . IV . To evaluate value early change level serum interleukin 6 ( IL-6 ) macrophage inflammatory protein 1 alpha ( MIP-1Î± ) predictor response bortezomib/pegylated liposomal doxorubicin . V. To correlate pre-treatment clinical biological characteristic response therapy toxicity . OUTLINE : Patients receive bortezomib intravenously ( IV ) 3-5 second day 1 , 4 , 8 , 11 pegylated liposomal doxorubicin hydrochloride IV 1 hour day 4 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 week 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients must histologically confirm diagnosis symptomatic multiple myeloma evaluable disease parameter A diagnosis symptomatic multiple myeloma require : A monoclonal serum and/or urine protein Clonal bone marrow plasmacytosis , histologically confirm plasmacytoma Related organ tissue impairment , consist : Hypercalcemia ( serum calcium &gt; 0.25 mmol/l upper limit normal , &gt; 2.75 mmol/l [ i.e . &gt; 11.5 mg/dl ] ) AND/OR Renal insufficiency ( serum creatinine &gt; 173 mmol/l [ i.e. , &gt; 2 mg/dL ] ) ; ( please note serum creatinine may &gt; = 2.5 mg/dL ) AND/OR Anemia ( hemoglobin 2 g/dl low limit normal , hemoglobin &lt; 10 g/dl ) AND/OR Bony lesion ( lytic bony lesion , osteoporosis compression fracture ) AND/OR Other finding , symptomatic hyperviscosity , amyloidosis , recur bacterial infection ( &gt; 2 episode 12 month ) Patients may undergo prior therapy , follow exception : Prior plasmapheresis plasma exchange ( PLEX ) hyperviscosity syndrome allow , provide patient current evidence hyperviscosity require PLEX least one week prior initiation therapy Prior radiation therapy area spinal cord compression plasmacytoma , painful lesion due bony involvement , myelomarelated indication , allow provide radiation complete 3 week initiation therapy Prior surgical intervention , bony fracture myelomarelated complication , allow provide complete 3 week initiation therapy , patient recover surgery Prior therapy corticosteroid indication multiple myeloma allow , provide therapy discontinue least two week prior study entry , least two week baseline disease evaluation Prior supportive therapy bisphosphonates erythropoietin allow Inclusion female childbearing potential require negative pregnancy test Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Patients may prior history hypersensitivity reaction pegylated liposomal doxorubicin doxorubicin , bortezomib boronic acidbased compound Patients history reaction liposomal drug formulation pegylated liposomal doxorubicin evaluate individually , reaction felt due liposomal component , oppose encapsulated agent , exclude discretion investigator Patients know human immunodeficiency virus ( HIV ) seropositive take antiretrovirals may participate study ; patient HIVseropositive antiretroviral therapy , otherwise meet organ function criterion , eligible study Patients know active hepatitis A , B , C viral infection may participate study No electrocardiogram ( EKG ) evidence acute ischemia No EKG evidence medically significant conduction system abnormalities No history myocardial infarction within last 6 month Left ventricular ejection fraction ( LVEF ) must &gt; = 45 % either echocardiography radionuclidebased multiple gated acquisition ( radionuclide ventriculography [ RNV ] multiple gate acquisition scan [ MUGA ] ) No class 3 class 4 New York Heart Association congestive heart failure Creatinine &lt; 2.5 mg/dL Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 time upper limit institutional normal value Total bilirubin = &lt; 1.2 time upper limit institutional normal value Absolute neutrophil count ( ANC ) &gt; = 1,000/ul Platelets &gt; = 100,000/ul Hemoglobin &gt; = 8 g/dl ( transfusion and/or growth factordependent patient exclude parameter achieve support ) For patient receive warfarin ( Coumadin ) , unfractionated heparin , lowmolecular weight heparin therapy , applicable coagulation parameter monitor must within accept therapeutic range indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>